Navigation Links
InNexus Completes Previously Announced Private Placement
Date:1/27/2009

BRITISH COLUMBIA, Canada, Jan. 27 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), announced today that it has completed a second private placement on the same terms and conditions as the private placement that was completed 12 December 2008.

The private placement, totaled $2,207,000 of 10% unsecured convertible debentures. Each Debenture will be convertible into common shares of InNexus at the rate of one common share for each $0.10 of debt converted. The Debenture will have a term of 2 years. In the course of this private placement, InNexus has redeemed $624,000 in value of preferred shares which was reinvested by the holder of such redeemed preferred shares in the Debenture. Net proceeds from the private placement which is approximately $911,000 will be used by InNexus for research and development and general corporate business.

In connection with the private placement, certain insiders of InNexus comprised of the Chairman & CEO, some members of the Board and senior management, participated on the same terms in the offering for an aggregate of approximately 19% of the issued Debenture. InNexus paid a $7,000 finders' fee or 7% of the proceeds was paid to an investment company from the sale of the Debentures to purchasers referred by such finder in accordance with the policies of the TSX Venture Exchange.

Participation in the private placement by insiders of InNexus is considered to be a related-party transaction as defined under Multilateral Instrument 61-101. The transaction is, however, exempt from the formal valuation and minority shareholder approval requirements under the Instrument as neither the fair market value of the securities being issued nor the consideration paid exceeds 25 percent of InNexus' market capitalization.

Upon conversion of the Debenture,
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
2. InNexus Biotechnology Receives Patent Grants in Europe
3. InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
4. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
5. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
6. InNexus Biotechnology Strengthens Patent Team With New Leadership
7. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
8. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
9. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
10. DiFUSION Technologies Completes Successful Testing of Antimicrobial Spinal Implant
11. Mach One Completes Note Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... for Molecular Medicine Finland (FIMM), University of Helsinki, ... "man and machine" decision support system for diagnosing ... in PLOS One scientific journal today, ... vision algorithms similar to those used in facial ... diagnostically most relevant areas. Tablet computers can be ...
(Date:8/21/2014)... Aug. 21, 2014 Telomere Biosciences, LLC ... Nutraceutical "TELO-20 for Dogs" with Telomerase Activation ... in the world for dogs. Telomeres are the ... in the body. A wealth of ground-breaking research ... Telomere Science and Aging, including Nobel laureates, has ...
(Date:8/21/2014)... Cord Blood Corporation (NYSE: CO ) (the ... for the first quarter of fiscal year 2015 on ... US.  The Company will host a ... 29, 2014 to discuss its financial performance and give ... by a question and answer session.  Interested parties may ...
(Date:8/21/2014)... MA (PRWEB) August 21, 2014 ... company, has been recognized as one of the ... | 5000 magazine for the 2nd consecutive year. ... its 33rd annual Inc. 500|5000, an exclusive ranking ... represents the most comprehensive look at the most ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3
... Using proprietary platform, company develops first orally-administered ... large-animal model -, SAN FRANCISCO, Oct. 24 ... development of oral vaccines, today announced,positive efficacy results ... vaccine. Sean Tucker, PhD, Vaxart founder and vice ...
... receive $5 million over four years from the ... for Nanotechnology Applications and Career Knowledge (NACK). , ... nanotechnology education and workforce development since 1998. From ... the NSF Regional Center for Nanofabrication Manufacturing Education. ...
... (Nasdaq: KERX ) announced today that it ... stating that Nasdaq Marketplace Rule,4310(c)(4), which requires companies ... share, has been temporarily suspended. Based on this ... until January 23, 2009, to,achieve compliance with Rule ...
Cached Biology Technology:Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies 2Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies 3Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies 4Penn State gets $5M NSF grant for Nanotech Applications and Career Knowledge 2Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period 2
(Date:8/21/2014)... toxins in past decade, GTA still violates Canada,s ... while the Greater Toronto Area (GTA) has significantly ... smog, the city continues to violate the Canada-wide ... cause or aggravate health problems such as asthma, ... set of complex photochemical reactions involving volatile organic ...
(Date:8/21/2014)... Aug. 21, 2014 Nxt-ID, Inc. (OTCQB: NXTD), ... commerce market, announced today that its shares of common ... be issued in its proposed underwritten public offering of ... on The Nasdaq Capital Market, subject to closing of ... and warrants, and will trade under the symbol "NXTD" ...
(Date:8/21/2014)... are the ultimate source of all organic matter that ... algae, too, to suck up climate-warming carbon dioxide from ... the ocean. Now, by using a combination of satellite ... viruses infecting those algae are driving the life-and-death dynamics ... essentially the same, and this has important implications for ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Viruses take down massive algal blooms, with big implications for climate 2
... Rice University and North Carolina State University have found ... may help manufacturers reach beyond the current limits of ... more powerful. Their findings are published this month ... . Moore,s Law, suggested by Intel co-founder Gordon ...
... scientists at the University of Iowa shows why muscle membranes ... light on a mechanism that appears to protect cells from ... Proceedings of the National Academy of Sciences ( ... is so severe when this mechanism is disrupted, which occurs ...
... , , , ... its recent analysis of the automated optical inspection (AOI) equipment ... Frost & Sullivan Award for Product Innovation of the Year ... AOI system combines high-speed inspection with superior performance, accuracy, quality, ...
Cached Biology News:Silicon with afterburners: Process developed at Rice could be boon to electronics manufacturer 2Sticky protein helps reinforce fragile muscle membranes 2Frost & Sullivan Recognizes MIRTEC With the 2009 Award for Automated Optical Inspection Product Innovation of the Year 2Frost & Sullivan Recognizes MIRTEC With the 2009 Award for Automated Optical Inspection Product Innovation of the Year 3
Request Info...
Recommend to use at up to 5000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.)...
... Avidin is chromatographically purified from egg white. The ... 15.5.The product is in 10 mM phosphate-buffered ... serum albumin, 0.05% sodium azide and 50% glycerol. ... The conjugate is purified by molecular sieving ...
... The Zero Blunt TOPO ... Sequencing is designed for ... of blunt-end PCR products. ... 5-minute TOPO Cloning and ...
Biology Products: